CLAIMS

1. Use of a *Notch*-ligand in the manufacture of a medicament for use in immunotherapy.

2. Use according to claim ~~1~~, wherein the immunotherapy involves the treatment of a T-cell mediated disease or infection.

3. Use according to claim 2, wherein the T cell mediated disease or infection is due to of any one or more of allergy, autoimmunity, graft rejection, tumour induced abberations to the T cell system and infectious diseases such as those caused by Plasmodium species, Microfilariae, Helminths, Mycobacteria, HIV, Cytomegalovirus, Pseudomonas, Toxoplasma, Echinococcus, Haemophilus influenza type B, measles, Hepatitis C or Toxicara.

4. Use according to ~~any of claims 1 to 3,~~ Claim 1 wherein the *Notch*-ligand is selected from Serrate, Delta or fragments, derivatives or analogs thereof.

5. A *Notch*-ligand, or fragments, derivatives or analogs thereof, for use in affecting linked suppression.

6. A *Notch*-ligand, or fragments, derivatives or analogs thereof, for use in affecting infectious tolerance.

7. A method of tolerising T cells to an allergen or antigen comprising incubating/exposing said T cells to antigen presenting cells expressing or overexpressing a *Notch*-ligand; in the presence of said allergen or antigen.

8. A method according to claim ~~7,~~ wherein the (over)expression of the *Notch*-ligand is due to the APC being transfected with a virus capable of expressing said ligand.

9. A method according to claim 7, wherein the (over)expression of the *Notch*-ligand is due to the APC being stimulated by an agent that up-regulates expression of a *Notch*-ligand expressing gene.

10. A method according to claim 9, wherein the agent is selected from Noggin, Chordin, Follistatin, Xnr3, fibroblast growth factors or derivatives or fragments thereof.

11. A method according to ~~claim 7, 8, 9 or 10~~ CLAIM 7 wherein the APC is selected from dendritic cells, L cells, hybridomas, lymphomas, macrophages, B cells or synthetic APCs such as lipid membranes.

12. A method according to ~~any of claims 7 to 11,~~ CLAIM 7 wherein the *Notch*-ligand is selected from Serrate, Delta or fragments, derivatives or analogs thereof.

13. A molecule comprising a *Notch*-ligand moiety operably linked to a T cell allergen or antigen moiety such that upon exposure to T cells both moieties are capable of binding to their respective sites.

14. A molecule according to claim 12 ~~or 13,~~ wherein the *Notch*-ligand moiety is selected from *Serrate, Delta* or fragments, derivatives or analogs thereof.

15. A fusion protein comprising a segment of a *Notch* ligand extracellular domain and an immunoglobulin F_c segment.

16. A fusion protein according to claim 15 wherein the *Notch* ligand extracellular domain is derived from *Notch*, *Delta* or *Serrate*.

17. A fusion protein according to claim 15 ~~or 16~~ wherein the F_c segment is $IgGF_c$ or $IgMF_c$

18. A kit comprising immobilised *Notch* or family members to allow measurement of soluble *Notch* ligands originating from pathogens, transplanted grafts or cells of the host.

19. An assay method comprising contacting (a) a *Notch* protein and a ligand capable of binding to the *Notch* protein with (b) a compound; and determining if the compound affects binding of the ligand to the *Notch* protein.

20. A ligand capable of binding to *Delta* or *Serrate* proteins or their derivatives expressed on or secreted by pathogenic organisms, tumours or transplanted grafts, for use in medical therapy.

21. An assay method comprising determining the in vivo level of soluble free *Serrate*, *Notch* or *Delta* family members or forms thereof.

22. An assay for detecting the affect of a compound on the expression or processing of functional *Notch*-protein or *Notch* ligand comprising contacting

cells expressing *Notch*-protein or *Notch* ligand with a compound; and monitoring an increase or decrease in expression or processing of said protein or ligand.

23. Compounds, *Notch*-legands, derivatives, fragments or analogs thereof, detectable by the assay of claim 22.

24. Use of an agent capable of downregulating the expression of *Delta* or *Serrate* proteins or reducing its presentation as a cell membrane protein in the manufacture of a medicament for use in reversing bacteria, infection or tumour-induced immunosuppression.

25. Use according to claim 24, wherein the agent is a Toll protein or bone morphogenetic protein.

26. Use of a *Notch*-ligand in the modulation of the expression of a functional *Notch*-protein or *Notch* signalling pathways.